Myotonic dystrophy type 2: the 2020 update.

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Myotonic dystrophies (DM1 and DM2) are leading causes of adult-onset muscular dystrophy.
• These conditions are increasingly understood as 'spliceopathies,' originating from RNA defects rather than protein abnormalities.
• Despite overlapping phenotypes, DM1 and DM2 present distinct clinical and genetic profiles.

Purpose of the Study:

• To delineate the key differences between myotonic dystrophy type 1 and type 2.
• To highlight the distinct diagnostic and management approaches required for DM1 and DM2.
• To discuss the future prospects of gene therapy for these conditions.

Main Methods:

• Comparative analysis of clinical phenotypes, including congenital presentation, affected muscle groups, and fiber type involvement.
• Review of molecular pathogenesis focusing on RNA-mediated mechanisms.
• Assessment of current management strategies and emerging therapeutic options like gene therapy.

Main Results:

• DM1 and DM2 exhibit differences in congenital form, primary muscle involvement (distal vs. proximal), and affected muscle fiber types (Type I vs. Type II).
• Both are RNA-based spliceopathies, underscoring a shared molecular basis despite distinct genetic underpinnings.
• Effective management reduces patient morbidity and mortality, though no cure currently exists.

Conclusions:

• Myotonic dystrophy type 1 and type 2 are distinct genetic disorders requiring individualized diagnostic and therapeutic strategies.
• The understanding of spliceopathies offers new insights into disease mechanisms.
• Gene therapy holds significant promise for the future treatment of both DM1 and DM2, offering hope for patients.